Loading…
A novel polymorphism of the gene encoding furin, a TGF-β1 activator, and the influence on cardiac allograft vasculopathy formation
Background: Coronary vasculopathy (CV) is an important determinant of survival following cardiac transplantation. We have previously shown that G915C polymorphism of the Transforming Growth Factor-β1 (TGF-β1) gene strongly influences CV development. Furin is a proprotein convertase enzyme important...
Saved in:
Published in: | Transplant immunology 2004-11, Vol.13 (3), p.185-190 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background: Coronary vasculopathy (CV) is an important determinant of survival following cardiac transplantation. We have previously shown that G915C polymorphism of the Transforming Growth Factor-β1 (TGF-β1) gene strongly influences CV development. Furin is a proprotein convertase enzyme important in TGF-β1 activation. We investigated for polymorphism within the promoter region of the gene for furin (
fur). Allelic variation of the
fur gene, in conjunction with TGF-β1 polymorphism, was subsequently related to the development of CV.
Methods and Results: The
fur gene promoter region (position −1199 to +39) was analysed by SSCP and sequencing. A C/T single nucleotide substitution polymorphism at position −231* was identified. Using PCR the
fur and
TGFB1 genotypes were identified in 115 cardiac transplant recipients. CV was diagnosed at routine surveillance post-transplant coronary angiography.
Fur polymorphism had no influence on vasculopathy development; median time to diagnosis, *C/C homozygotes, 2.27 years (2.10–4.32), *C/T heterozygotes 2.97 years (2.09–4.24), *T/T homozygotes 2.65 years (2.33–4.08), (
P=0.95). Allelic variation did not influence Kaplan Meier actuarial analysis of disease onset (
P=0.54). Ninety-three percent of recipients were high TGF-β1 producers. We used
fur polymorphism to substratify patients with the +915*G/G
TGFB1 (high producing) allele.
Fur polymorphism did not influence CV development within this TGF-β1 high producer cohort, when analysed by time to first diagnosis and Kaplan Meier testing.
Conclusions: We have described a novel polymorphism at position −231* in the gene encoding furin. The
fur −231* single nucleotide polymorphism in isolation, or in conjunction with
TGFB1 polymorphism, is not useful as a genetic risk marker for cardiac transplant associated coronary vasculopathy. |
---|---|
ISSN: | 0966-3274 1878-5492 |
DOI: | 10.1016/j.trim.2004.04.005 |